Cancer Research and Treatment

Original Article

Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes: Euna Cho, S M Bakhtiar Ul Islam, Fen Jiang, Ju-Eun Park, Bora Lee, Nam Deuk Kim, Tae-Ho Hwang; Cancer Res Treat. 2020;52(1):309-319. Published online August 6, 2019; DOI: https://doi.org/10.4143/crt.2019.161

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to assess characteristics of SJ-815, a novel oncolytic vaccinia virus lacking a functional thymidine kinase-encoding TK gene, and instead, having two human transgenes: the IFNB1 that encodes interferon β1, and the CES2 that encodes carboxylesterase 2, which metabolizes the prodrug, irinotecan, into cytotoxic SN-38.
Materials and Methods
Viral replication and dissemination of SJ-815 were measured by plaque assay and comet assay, respectively, and compared to the backbone of SJ-815, a modified Western Reserve virus named WI. Tumor cytotoxicity of SJ-815 (or mSJ-815, which has the murine IFNB1 transgene for mouse cancers) was evaluated using human and mouse cancer cells. Antitumor effects of SJ-815, with/without irinotecan, were evaluated using a human pancreatic cancer-bearing mouse model and a syngeneic melanoma-bearing mouse model. The SN-38/ irinotecan ratios in mouse melanoma tissue 4 days post irinotecan treatment were compared between groups with and without SJ-815 intravenous injection.
Results
SJ-815 demonstrated significantly lower viral replication and dissemination, but considerably stronger in vitro tumor cytotoxicity than WI. The combination use of SJ-815 plus irinotecan generated substantial tumor regression in the human pancreatic cancer model, and significantly prolonged survival in the melanoma model (hazard ratio, 0.11; 95% confidence interval, 0.02 to 0.50; p=0.013). The tumor SN-38/irinotecan ratios were over 3-fold higher in the group with SJ-815 than those without (p < 0.001).
Conclusion
SJ-815 demonstrates distinct characteristics gained from the inserted IFNB1 and CES2 transgenes. The potent antitumor effects of SJ-815, particularly when combined with irinotecan, against multiple solid tumors make SJ-815 an attractive candidate for further preclinical and clinical studies.

Citations

Citations to this article as recorded by

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer
Won Suk Lee, Seung Joon Lee, Hye Jin Lee, Hannah Yang, Eun-Jin Go, Enkhtaivan Gansukh, Ki-Hoon Song, Xiao Xiang, Dong Guk Park, Tommy Alain, Hong Jae Chon, Chan Kim
Nature Communications.2024;[Epub] CrossRef
CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1), the next medical revolution against cancer
Ali Adel Dawood
Vacunas.2023; 24(4): 358. CrossRef
CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1), the next medical revolution against cancer
Ali Adel Dawood
Vacunas (English Edition).2023; 24(4): 358. CrossRef
An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer
Maryum Nisar, Rehan Zafar Paracha, Sidra Adil, Sumair Naseem Qureshi, Hussnain Ahmed Janjua
Frontiers in Oncology.2022;[Epub] CrossRef
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
Seung Joon Lee, Hannah Yang, Woo Ram Kim, Yu Seong Lee, Won Suk Lee, So Jung Kong, Hye Jin Lee, Jeong Hun Kim, Jaekyung Cheon, Beodeul Kang, Hong Jae Chon, Chan Kim
Journal for ImmunoTherapy of Cancer.2021; 9(6): e002195. CrossRef
Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing
Tomoyoshi Inoue, Thomas Byrne, Mitsuko Inoue, Madeline E. Tait, Patrick Wall, Annabel Wang, Michael R. Dermyer, Hanane Laklai, Joseph J. Binder, Clare Lees, Robert Hollingsworth, Liliana Maruri-Avidal, David H. Kirn, Donald M. McDonald
Molecular Cancer Therapeutics.2021; 20(8): 1481. CrossRef
Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase
S. M. Bakhtiar Ul Islam, Bora Lee, Fen Jiang, Eung-Kyun Kim, Soon Cheol Ahn, Tae-Ho Hwang
Cancers.2020; 12(1): 228. CrossRef

11,351 View
255 Download
5 Web of Science
7 Crossref

First
Prev
Page of 1
Next
Last

Search